Collectively, these findings indicate that genetic disruption of PD-1 enhances the anti-tumor effect of LA HER2-28Z CAR-T cells in tumors expressing PD-L1, while it does not impact the efficacy of HA CAR-T cells. The gene discussed is PDCD1; the disease is neoplasm.